Plasma-based circulating microRNA biomarkers for Parkinson's disease

Journal of Parkinson's Disease

Volumn 2, Issue 4, 2012, Pages 321-331

  Khoo, Sok Kean ^a,e   Petillo, David ^a   Kang, Un Jung ^b   Resau, James H ^a   Berryhill, Brian ^c   Linder, Jan ^d   Forsgren, Lars ^d   Neuman, Leslie A ^c  

^a VAN ANDEL INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Saint Mary's Health Care   (United States)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; Circulating microRNAs; Parkinson's disease; plasma

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1225 5P; MICRORNA 1253; MICRORNA 1307; MICRORNA 1826; MICRORNA 192; MICRORNA 200A; MICRORNA 222; MICRORNA 450B 3P; MICRORNA 455 3P; MICRORNA 485 5P; MICRORNA 488; MICRORNA 505; MICRORNA 506; MICRORNA 518C; MICRORNA 579; MICRORNA 626; MICRORNA 632; MICRORNA 647; MICRORNA 708; MICRORNA 891B; MICRORNA 99A; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; GENETIC ALGORITHM; HUMAN; MALE; MICROARRAY ANALYSIS; PARKINSON DISEASE; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY;

EID: 84874894477     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-012144     Document Type: Article

References (42)

1. Sherer TB (2011) Biomarkers for Parkinson's disease. Sci Transl Med, 3, 79ps14.
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schi-fitto G, Siderowf A, & Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations 2005 through 2030. Neurology, 68, 384-386. (Pubitemid 46184217)
3. Hughes AJ, Daniel SE, Ben-Shlomo Y, & Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain: A Journal of Neurology, 125, 861-870. (Pubitemid 34279780)
4. van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groe-newegen HJ, Berendse HW, & van de Berg WD (2010) Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. Neurobiology of Disease, 39, 229-241.
5. Breen DP, Michell AW, & Barker RA (2011) Parkinson's disease-the continuing search for biomarkers. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC, 49, 393-401.
6. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Mon-tine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, & Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain: A journal of Neurology, 133, 713-726.
7. Liotta LA, Ferrari M, & Petricoin E (2003) Clinical pro-teomics: Written in blood. Nature, 425, 905.
8. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, & Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain: A Journal of Neurology, 129, 3042-3050. (Pubitemid 44684524)
9. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Kary-das A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, & Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine, 13, 1359-1362. (Pubitemid 350073592)
10. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, & Diaz-Arrastia R (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Archives of Neurology, 67, 1077-1081.
11. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, & Trojanowski JQ (2011) Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology, 69, 655-663.
12. Bilen J, Liu N, Burnett BG, Pittman RN, & Bonini NM (2006) MicroRNA pathways modulate polyglutamine-induced neu-rodegeneration. Mol Cell, 24, 157-163. (Pubitemid 44466675)
13. Schaefer A, O'Carroll D, Tan CL, Hillman D, Sugimori M, Llinas R, & Greengard P (2007) Cerebellarneurodegeneration in the absence of microRNAs. J Exp Med, 204, 1553-1558.
14. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, & Abeliovich A (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science, 317, 1220-1224.
15. Zovoilis A, Agbemenyah HY, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P, Farinelli L, Delalle I, Schmitt A, Falkai P, Bahari-Javan S, Burkhardt S, Sananbenesi F, & Fischer A (2011) microRNA-34c is a novel target to treat dementias. The EMBO Journal, 30, 4299-4308.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, & Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academyof Sciences of the UnitedStates of America, 105, 10513-10518.
17. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, & Bjorkqvist M (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Human Molecular Genetics, 20, 2225-2237.
18. Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J, Nazarov PV, Palissot V, Hood LE, Berchem G, & Galas DJ (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 108, 6573-6578.
19. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M, Garcia-Manero G, & Bueso-Ramos CE (2011) Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood, 118, 413-415.
20. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarn-era M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, & Jiang F (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Laboratory Investigation; A Journal of Technical Methods and Pathology, 91, 579-587.
21. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, & Liu S (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PloS One, 5, e13735.
22. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P, Achilli F, Martelli F, Mag-giolini S, Marenzi G, Pompilio G, & Capogrossi MC (2010) Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. European Heart Journal, 31, 2765-2773.
23. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, & Sung JJ (2009) Differential expression of microR-NAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut, 58, 1375-1381.
24. Hughes AJ, Daniel SE, Kilford L, & Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological studyof100 cases.Journal of Neurology, Neurosurgery, and Psychiatry, 55, 181-184.
25. Tan AC, Naiman DQ, Xu L, Winslow RL, & Geman D (2005) Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics, 21, 3896-3904. (Pubitemid 41535505)
26. Tusher VG, Tibshirani R, & Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America, 98, 5116-5121. (Pubitemid 32397092)
27. Newton MA, Kendziorski CM, Richmond CS, Blattner FR, & Tsui KW (2001) On differential variability of expression ratios: Improving statistical inference about gene expression changes from microarray data. Journal of Computational Biology:AJournalof Computational Molecular Cell Biology, 8, 37-52. (Pubitemid 32679478)
28. Livak KJ, & Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408. (Pubitemid 34164012)
29. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, & Trojanowski JQ (2010) Biomarker discovery for Alzheimer's disease, fron-totemporal lobar degeneration, and Parkinson's disease. Acta Neuropathologica, 120, 385-399.
30. Cortez MA, & Calin GA (2009) MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. Expert Opinion on Biological Therapy, 9, 703-711.
31. Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L (2012) Circulating microRNAs involved in multiple sclerosis. Molecular Biology Reports, 39, 6219-6225.
32. Verduci L, Simili M, Rizzo M, Mercatanti A, Evan-gelista M, Mariani L, Rainaldi G, & Pitto L (2010) MicroRNA (miRNA)-mediated interaction between leukemia/lymphoma-related factor (LRF) and alternative splicing factor/splicing factor 2 (ASF/SF2) affects mouse embryonic fibroblast senescence and apoptosis. The Journal of Biological Chemistry, 285, 39551-39563.
33. Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, Huang M, & Yu AM (2011) MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Bio-pharmaceutics & Drug Disposition, 32, 355-367.
34. Margis R, & Rieder CR (2011) Identification of blood microRNAs associated to Parkinsonis disease. Journal of Biotechnology, 152, 96-101.
35. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, & Vives F (2010) Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Movement Disorders: Official Journal ofthe MovementDisorder Society, 25, 489-493.
36. Orlova IA, Alexander GM, Qureshi RA, Sacan A, Graziano A, Barrett JE, Schwartzman RJ, & Ajit SK (2011) MicroRNA modulation in complex regional pain syndrome. Journal of Translational Medicine, 9, 195.
37. Mayeux R (2004) Biomarkers: Potential uses and limitations. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, 1, 182-188. (Pubitemid 46589350)
38. Reijn TS, Rikkert MO, van Geel WJ, de Jong D, & Verbeek MM (2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clinical Chemistry, 53, 859-865. (Pubitemid 46744241)
39. Hobert O (2008) Gene regulation by transcription factors and microRNAs. Science, 319, 1785-1786. (Pubitemid 351451553)
40. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, & Dimitrov K (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature Biotechnology, 26, 317-325. (Pubitemid 351355126)
41. Salta E, & De Strooper B (2012) Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurology, 11, 189-200.
42. Qureshi IA, & Mehler MF (2012) Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nature Reviews. Neuroscience, 13, 528-541.